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ABSTRACT
Respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract infections in infants. Despite over 50 years of
research, to date no safe and efficacious RSV vaccine has been licensed. Many experimental vaccination strategies failed to induce
balanced T-helper (Th) responses and were associated with adverse effects such as hypersensitivity and immunopathology upon
challenge. In this study, we explored the well-established recombinant vaccinia virus (rVV) RSV-F/RSV-G vaccination-challenge
mouse model to study phenotypically distinct vaccine-mediated host immune responses at the proteome level. In this model,
rVV-G priming and not rVV-F priming results in the induction of Th2 skewed host responses upon RSV challenge. Mass spec-
trometry-based spectral count comparisons enabled us to identify seven host proteins for which expression in lung tissue is asso-
ciated with an aberrant Th2 skewed response characterized by the influx of eosinophils and neutrophils. These proteins are in-
volved in processes related to the direct influx of eosinophils (eosinophil peroxidase [Epx]) and to chemotaxis and extravasation
processes (Chil3 [chitinase-like-protein 3]) as well as to eosinophil and neutrophil homing signals to the lung (Itgam). In addi-
tion, the increased levels of Arg1 and Chil3 proteins point to a functional and regulatory role for alternatively activated macro-
phages and type 2 innate lymphoid cells in Th2 cytokine-driven RSV vaccine-mediated enhanced disease.
IMPORTANCE
RSV alone is responsible for 80% of acute bronchiolitis cases in infants worldwide and causes substantial mortality in develop-
ing countries. Clinical trials performed with formalin-inactivated RSV vaccine preparations in the 1960s failed to induce protec-
tion upon natural RSV infection and even predisposed patients for enhanced disease. Despite the clinical need, to date no safe
and efficacious RSV vaccine has been licensed. Since RSV vaccines have a tendency to prime for unbalanced responses associated
with an exuberant influx of inflammatory cells and enhanced disease, detailed characterization of primed host responses has
become a crucial element in RSV vaccine research. We investigated the lung proteome of mice challenged with RSV upon prim-
ing with vaccine preparations known to induce phenotypically distinct host responses. Seven host proteins whose expression
levels are associated with vaccine-mediated enhanced disease have been identified. The identified protein biomarkers support
the development as well as detailed evaluation of next-generation RSV vaccines.
Respiratory syncytial virus (RSV) is the leading cause of severelower respiratory tract infections in children, being responsi-
ble for up to 80% of the cases of acute bronchiolitis and frequent
subsequent hospital admission in industrialized countries (1, 2). It
has been estimated that RSV causes 33.8 million acute lower re-
spiratory tract infections globally each year, resulting in 66,000 to
199,000 deaths among children under 5 years of age, 99%ofwhich
occur in developing countries (3). In addition to young children,
immunocompromised individuals and the elderly are at increased
risk for severe RSV disease and hospitalization. A licensed RSV
vaccine is currently not available, and the development of a vac-
cine against RSV infection has proven to be very difficult. Forma-
lin-inactivated RSV (FI-RSV) vaccine trials in the 1960s failed to
induce protection upon natural RSV infection and even predis-
posed patients for enhanced disease, resulting in two deaths and
hospitalization of 80% of the vaccinated subjects (4–7). Experi-
mental inactivated and subunit vaccines tend to prime for the
induction of unbalanced, type 2 T-helper (Th2) host responses
that result in enhanced disease accompanied by an influx of in-
flammatory cells (8). On the other hand, development of live at-
tenuated RSV vaccines that are more likely to induce balanced
host responses appears difficult to tune and these live vaccines
tend either to be over- or underattenuated (9, 10). Several RSV
infection animal models have been developed, and these are ex-
ploited for vaccine research and studies on virus-induced (immu-
no)pathology. Multiple virological and immunological parame-
Received 18 December 2014 Accepted 13 February 2015
Accepted manuscript posted online 18 February 2015
Citation van Diepen A, Brand HK, de Waal L, Bijl M, Jong VL, Kuiken T, van
Amerongen G, van den Ham H-J, Eijkemans MJ, Osterhaus ADME, Hermans PWM,
Andeweg AC. 2015. Host proteome correlates of vaccine-mediated enhanced
disease in a mouse model of respiratory syncytial virus infection. J Virol
89:5022–5031. doi:10.1128/JVI.03630-14.
Editor: D. S. Lyles
Address correspondence to Arno C. Andeweg, a.andeweg@erasmusmc.nl.
* Present address: Angela van Diepen, Center of Infectious Diseases, Department
of Parasitology, Leiden University Medical Center, Leiden, The Netherlands; Peter
W. M. Hermans, Janssen—Johnson and Johnson, Leiden, The Netherlands.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.
doi:10.1128/JVI.03630-14
5022 jvi.asm.org May 2015 Volume 89 Number 9Journal of Virology
 o
n
 M
arch 6, 2017 by UNIVERSITEITSBIBLIO
THEEK
http://jvi.asm.org/
D
ow
nloaded from
 
ters are assessed in these studies to monitor the virus-host
interaction.More recently, “high-resolution” genomics tools have
also been applied, in particular, to characterize the host response.
Previously, the FI-RSV mouse model had been used to character-
ize the host lung response in enhanced disease bymRNA profiling
(11), and several host gene expression correlates of enhanced dis-
ease have been identified. Since it has been shown that immuni-
zation with formalin-inactivated mock antigen vaccine, like im-
munization with FI-RSV itself, also primes for Th2 skewed
responses in the FI-RSV mouse model (12), we explored the re-
combinant vaccinia virus F (rVV-F)/rVV-G vaccination-chal-
lenge model of enhanced disease for which the induced disease
phenotype depends only on the expression of the RSV F or G
protein. For thismodel, it has been shown that vaccination ofmice
with rVV-G results in the production of neutralizing antibodies
and subsequent reductions in RSV replication upon challenge in-
fection (13, 14). However, these mice develop severe illness and
pulmonary eosinophilia. Therefore, this model is ideally suited to
the study of vaccine-enhanced disease upon RSV infection. Simi-
larly to rVV-G priming, priming with rVV-F results in the pro-
duction of neutralizing antibodies but induces a more effective
immunity to viral replication than priming with rVV-G (13),
without the pulmonary eosinophilia seen upon RSV challenge.
Using this mouse model of vaccine-enhanced disease and ap-
plying mass spectrometry (MS)-assisted protein profiling, we
studied the molecular mechanism underlying vaccine-induced
RSV-specific enhanced disease. With a comparative proteomics
approach, we identified seven proteins as biomarkers of enhanced
disease. These proteins include eosinophil peroxidase (Epx), chiti-
nase-like-protein 3 (Chil3), and Itgam, representing proteins spe-
cific for the infiltrating eosinophils. In addition, proteins that are
postulated to play a role in the preceding stages of induction and
establishment of skewed vaccine-induced hypersensitivity re-
sponses, arginase-I (ArgI), Clca3, purine-rich element-binding
protein beta (PurB), and hexokinase III (Hk3), have also been
identified. These seven protein biomarkers can be used to support
the development, as well as the detailed evaluation, of next-gen-
eration RSV vaccines.
MATERIALS AND METHODS
Cells and viruses. HEp-2 and RK-13 cells were cultured in Dulbecco’s
modified Eagle’s medium (DMEM) and RPMI 1640, respectively (both
BioWhittaker, Verviers, Belgium), supplemented with 10% heat-inacti-
vated fetal bovine serum (HI-FBS; Greiner, Frickenhausen, Germany),
penicillin (BioWhittaker) (100 U/ml), streptomycin (BioWhittaker) (100
g/ml), L-glutamine (BioWhittaker) (2 mM), and -mercaptoethanol
(Merck, Darmstadt, Germany) (10 to 5M) at 37°Cwith 5%CO2. RSV-A2
(a kind gift from P. J. M. Openshaw, National Heart and Lung Institute,
Centre for Respiratory Infection, Imperial College London, London,
United Kingdom) was propagated on HEp-2 cells. Recombinant vaccinia
viruses (13) were kindly provided by P. L. Collins (National Institutes of
Health, Bethesda, MD, USA). Stocks of the parental vaccinia virus (VV-
wt) and recombinant vaccinia viruses expressing the RSV fusion protein
(rVV-F) and attachment protein (rVV-G) were produced on RK-13 cells.
Infectivity of all virus stocks was checked on the corresponding cell line by
serial 10-fold dilutions, and titers were calculated using the method of
Reed and Muench (15).
Mouse vaccination and challenge studies. Six-to-8-week-old female
BALB/c mice (Netherlands Vaccine Institute, Bilthoven, The Nether-
lands) were vaccinated by scarification at the tail base with 106 PFU VV-
wt, rVV-F, or rVV-G as described before (14, 16). Three weeks after vac-
cination, the mice were challenged by intranasal inoculation with 5 106
50% tissue culture infectious doses (TCID50) of RSV-A2. Weight was
measured on a daily basis, and mice were sacrificed by exsanguination
under isoflurane anesthesia at 1, 2, 3, 5, and 7 days after RSV challenge (10
animals per group per day). Five animals from each group were subjected
to bronchoalveolar lavage (BAL). Subsequently, lungs were inflated with
10% neutral buffered formalin (formalin; Klinipath, Duiven, The Neth-
erlands) and stored in 10% formalin for histopathological examination.
The lungs of five other animals per group were dissected. Half of the lungs
were transferred to virus transport medium for virus isolation, while the
other half were stored in RNAlater (Ambion, Austin, TX, USA) for RNA
and protein isolation. To obtain control samples, naive age-matched an-
imals were sacrificed and processed identically. The study was approved
by the Animal Ethics Committee and was carried out in accordance with
animal experimentation guidelines.
BAL fluid phenotyping. Cells in BAL fluid were analyzed by flow
cytometry as described before (17). In short, BAL fluid samples were cen-
trifuged and residual red blood cells were lysed using red blood cell lysis
buffer (Roche Diagnostics GmbH, Mannheim, Germany) for 20 min at
room temperature. Cells in BAL fluid were counted and labeled with
fluorescent monoclonal antibodies in phosphate-buffered saline (PBS)
supplemented with 3%HI-FBS for 60min on ice. Next, cells were washed
once with PBS and subjected to fluorescence-activated cell sorter (FACS)
analysis.
Virus isolation. Virus was isolated from lung tissue by homogenizing
half of the lung in 1 ml virus transport medium in a Fastprep-24 instru-
ment (MPbio, Illkirch, France) using ceramic spheres (VWR Interna-
tional, Radnor, PA, USA) (0.25-in. diameter) according to the manufac-
turer’s protocol (20 min and 10 m/s). The homogenate was clarified by
centrifugation, and the supernatant was applied on amonolayer ofHEp-2
cells in serial 2-fold dilutions. Cells were screened microscopically for
cytopathic effect (cpe), and TCID50 values were calculated as described
above.
Protein isolation. After removal of the RNAlater, the lungs were ho-
mogenized and lysed in TRIzol and proteins were isolated from the inter-
phase and organic phase that remained after RNA extraction fromTRIzol
samples. Four volumes of ice-cold (20°C) acetone was added to these
fractions and incubated at20°C for 1 h. Precipitated proteins were then
centrifuged at maximum speed for 5 min. The protein pellet was washed
twice with ice-cold 80% acetone. The pellet was air-dried and suspended
in 40 l of lysis buffer containing 30 mM Tris, 7 M urea, 1 M thiourea,
and 4% 3-[(3-cholamidopropyl)-dimethylammonio]-1-propanesulfon-
ate (CHAPS). The protein concentration in each sample was determined
using a two-dimensional (2-D) Quant kit (GE Healthcare, Amersham,
United Kingdom) according to the manufacturer’s instructions.
Mass spectrometry. A total amount of 25g protein was loaded onto
a 12% SDS-PAGE gel and run at 100 V until the front reached the bottom
of the gel. The gel was stained overnight with Coomassie blue silver. Each
lanewas divided into 5 slices, and each slicewas cut into smaller pieces and
prepared for protein digestion with trypsin. Peptides were extracted using
2% trifluoroacetic acid (TFA) and buffer B (80% acetonitrile [ACN],
0.5% acetic acid, 1% TFA) and subsequently desalted and concentrated
using C18 StageTips and buffer A (0.5% acetic acid, 1% TFA). Peptide
mixtures were purified and desalted using C18 StageTips. Peptide separa-
tion and sequence determination were performed with a nano-high-per-
formance liquid chromatography system (Agilent 1100 series; Agilent,
Amstelveen, The Netherlands) connected to a 7-T linear quadrupole-ion
trap-ion cyclotron resonance (ICR) Fourier transform (FT) mass spec-
trometer (Thermo Electron, Breda, The Netherlands). Peptides were sep-
arated on a PicoTip emitter for online electrospray (New Objective,
Woburn, MA) (15-cm length, 100-m inner diameter) packed with
3-m-diameter C18 beads (Reprosil; Dr Maisch GmbH, Ammerbuch-
Entringen, Germany) with a 60-min linear gradient of 2.4% to 40% ace-
tonitrile–0.5% acetic acid at a 300 nl/min flow rate. The four most abun-
dant ions were sequentially isolated and fragmented in the linear ion trap
by applying collisionally induced dissociation. Proteins were identified
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using theMASCOT search engine (Matrix Science, London,UnitedKing-
dom) and the human International Protein Index (IPI) database (forward
and reverse sequences) and the following search criteria: 20 ppm peptide
tolerance, a maximum of 2 missed cleavages, a fixed carbamidomethyl
modification of cysteines, and variable oxidation (M) and deamidation
(NQ) modification. A UniProt KB mapping table was used to map IPI
identifiers (IDs) to UniProt IDs (ftp://ftp.uniprot.org/pub/databases
/uniprot/current_release/knowledgebase/idmapping/). Differentially ex-
pressed proteins were functionally classified using GO-slim identifiers
(18) and Ingenuity pathway analysis (Qiagen, Redwood City, CA, USA).
Validation of peptides and proteins. Mascot database search files
were further processed usingMSQuant 1.4.3 to generate first-ranked pep-
tide lists. A validation filter was applied to these lists using the reverse
database searches. First, themass accuracy cutoff value was set at themass
relative error (in parts per million [ppm]) at which 95% of all identified
peptides were still included. Then, the reverse database search was used to
set the peptide cutoff score at which only 10% of the identified peptides
were still included in the reverse database search list. The number of
peptide sequences per protein was then calculated, and the list was further
validated by the following criteria. Proteins that were identified on the
basis of 3 or more peptides were accepted. If 2 peptides were identified,
those peptides were not allowed to contain any modifications. If only 1
peptide was identified, no modifications were accepted, peptide scores
had to be above 40, and the peptide delta score had to be above 10. This
resulted in false-positive rates of 11% for proteins identified with 1 or 2
peptides and 0.9% for proteins identified with 3 or more peptides. After
internal calibration of peptides masses byMSQuant and validation as just
described, the absolute mass accuracy of all identified peptides was below
15 ppm for all samples, with an average of 2 ppm. To remove redun-
dancy at the protein level and to uniquely assign peptides to one protein,
the peptides were remapped using Protein Coverage Summarizer (http:
//ncrr.pnl.gov/software/).
Comparative protein expression analyses. For each protein in the
validated list of proteins, the number of unique parent ions (spectral
count) was calculated based on peptide sequences andmodifications. The
number of spectra matched to peptides from a protein is used as a surro-
gate measure of protein abundance (19). A negative binomial model that
handles overdispersion (20, 21) caused by limited numbers of biological
replicates is used to estimate the per-protein counts. To test for differen-
tial levels of expression between two conditions, the mean of the normal-
ized per-protein counts under each condition is computed and themeans
are compared for equality. An exact P value, defined as the probability of
a pair of observed counts, is computed as described in reference 22. After
computing the normalizedmean counts under each set of conditions and
the corresponding P values, we controlled for multiple testing by control-
ling the false-discovery rate (FDR), which was defined as the expected
proportion of false rejection among the rejected hypotheses, using the
Benjamini and Hochberg (BH) procedure.
RESULTS
Induction of skewed immune responses in an RSV vaccination-
challenge mouse model. BALB/c mice were primed with rVV-F,
rVV-G, or VV-wt and challenged with RSV. Body weight, viral
titers in the lungs, and the cellular composition of BAL fluid sam-
ples were measured, and histopathological examination of the
lungs was performed for a period of 7 days. Body weight measure-
ments showed that VV-wt-primed animals remained at the start-
ing weight upon challenge with RSV (Fig. 1A). In contrast, ani-
mals that had been primed with the RSV fusion protein (rVV-F)
or with the RSV attachment protein (rVV-G) showed a reduction
in body weight to approximately 85%of the starting weight in 4 to
5 days. Subsequently, the rVV-F-primed animals returned to the
starting weight whereas the weight of the rVV-G-primed animals
remained low at 85% of the starting weight until the end of the
study at day 7 (Fig. 1A).
Virus could be isolated from lung homogenates from all ani-
mals in the VV-wt group. Virus titers from VV-wt-primed mice
thatmounted a primary immune response to RSV peaked at day 3
to a level of 106 TCID50/gram lung tissue. At any time point, the
highest titers obtained in rVV-F- or rVV-G-primed mice were at
least 10-fold lower than those obtained for the VV-wt-primed
mice. In addition, the virus titers in these groups of mice showed
an earlier (day 2) and much lower peak than that seen with VV-
wt-primed mice, pointing to partial protection from challenge in
rVV-F- and rVV-G-primed mice (Fig. 1B).
BAL fluid samples were obtained at days 1, 2, 3, 5, and 7 after
challenge, and the cellular composition was determined by FACS
analysis. Mice primed with VV-wt displayed a typical primary
response to RSV infection, with a relatively late andmodest influx
of cells during the experiment.Mice primedwith rVV-F displayed
the highest numbers of T cells, B cells, and dendritic cells in the
BAL fluid samples, while neutrophils and eosinophils were more
abundant in the BAL fluid samples obtained from rVV-G-primed
animals (Fig. 2). In contrast, eosinophil numbers in BAL fluid
samples were much higher in rVV-G-mediated secondary re-
sponses than in rVV-F- or rVV-wt-primed animals (Fig. 2D).
Histopathological examination of slides of lung samples ob-
tained from animals that were sacrificed at day 5 after challenge
FIG 1 Relative body weights (A) and replication-competent virus titers in the lung (B) of VV wild-type (VV-wt) (black dots)-, rVV-F (white dots)-, and rVV-G
(black triangles)-vaccinated mice up to 7 days following RSV challenge. Average numbers with standard errors are indicated.
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revealed that both VV-wt- and rVV-F-primed mice experienced
interstitial pneumonia characterized by marked peribronchiolar
and perivascular infiltrates. In contrast, rVV-G-primed animals
experienced a more severe form of bronchointerstitial pneumo-
nia, in some animals even leading to the formation of foci of necrosis
associated with the presence of viral antigen. Interestingly, rVV-G-
primed animals accounted for the highest level of positive staining of
viral antigenof all the groups.While eosinophilswere virtually absent
inVV-wt- andrVV-F-primedanimals, these cellswere readilydetect-
able in rVV-G-primed animals.Most eosinophils were located in the
perivascular and peribronchiolar infiltrates and, to a lesser degree, in
the alveolar walls and lumina (data not shown).
In line with the original observations obtained with this RSV
vaccination and challenge model (13, 14), the data collectively
demonstrate that the regimens of rVV-F and rVV-G priming in-
deed mediate the induction of distinct host response phenotypes
upon RSV challenge. The collected lung samples are a good sub-
strate to monitor protein expression profiles and to search for
differences between the different priming regimens.
Mass spectrometry-assisted protein profiling of phenotypi-
cally distinct host responses. Lungs collected 5 days after RSV
challenge were homogenized, and proteins were isolated and sub-
jected to Fourier transform ion cyclotron resonance tandem MS
(FT-ICR-MS/MS) analysis. The collected sample set was comple-
mented with identical lung samples obtained from naive mice.
Raw FT-ICR-MS/MS data were processed and validated. Between
2,247 and 2,547 distinct proteins were detected for each group of
mice. Comparing the different experimental groups of mice, a
large overlap in detected proteins was observed (Fig. 3A). Princi-
pal component analysis (PCA) of the normalized protein expres-
sion data (spectral counts) revealed two major clusters. One clus-
ter consists of VV-wt-primed and naive mouse-derived lung
samples, while the other consists of rVV-F and rVV-G lung sam-
ples, indicating that protein expression data determined for the
FIG 2 Cellular composition of BAL fluid. Total numbers of T cells (A), B cells (B), neutrophils (C), eosinophils (D), and dendritic cells (E) in BAL fluid from
VV-wt (black dots)-, rVV-F (white dots)-, and rVV-G (black triangles)-vaccinated mice were determined by FACS analyses. Average numbers with standard
errors are indicated.
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two latter groups are similar but are different from those deter-
mined for the naive and VV-wt-primed mice (Fig. 3B).
Next, we applied spectral count analysis to identify proteins
differentially expressed between the vaccination groups and naive
mice. In this analysis, the number of unique parent ions (spectral
counts) is used as a surrogate measure of protein abundance (19).
First, spectral counts were compared between VV-wt-, rVV-F-,
and rVV-G-vaccinated mice and naive control mice. Lungs from
VV-wt-vaccinated mice displayed the smallest changes in protein
expression, with only 3 down- and 3 upregulated proteins com-
pared to the results seen with naive mice (Fig. 3C). Vaccination
with rVV-F or rVV-G induced higher numbers and more pro-
nounced changes in protein expression (129 and 97 differentially
expressed proteins, respectively). The magnitude of these total
lung proteome changes reflects a relatively slow-developing pri-
mary immune response (VV-wt-primed animals) and a much-
faster-developing secondary response in the RSV-specific (rVV-F
and rVV-G) primed mice. Only 3 proteins were differentially ex-
pressed in all 3 vaccination groups (Fig. 3C). As expected on the
basis of the PCA data, a large overlap between the rVV-F-vacci-
natedmice and rVV-G-vaccinatedmice was observed, where 50%
to 67% of the proteins identified as differentially expressed with
respect to the results seen with the naive mice were also found to
be differentially expressed relative to those seen with the naive
mice in the other group. Regardless of the priming regimen
(rVV-F, rVV-G, or rVV-wt), differentially expressed proteins (rel-
ative to naivemice) shared between the experimental groups were
always up- or downregulated in the same direction. The rVV-F- and
rVV-G-primed responses are indeed highly similar: in a direct com-
parison of rVV-F- and rVV-G-primed lung tissue samples, only 7
proteins (Epx, Chil3, Itgam, Arg1, Clca3, PurB, and Hk3) are signif-
icantly differentially regulated (Table 1). Six of these proteins were
more abundantly present in lung tissue of rVV-G-primed mice: 2
proteins (Arg1andEpx)wereupregulated in rVV-G-primedsamples
relative to rVV-F-primed samples, and 4 (Itgam, Chi3l3, Clca3, and
Hk3) were unique to the rVV-G-primed samples. One protein
(PurB) was expressed in rVV-F-primedmice only.
As expected, RSV challenge after VV-wt priming led to only a
few differentially expressed proteins in lung tissue at day 5: Eif2s1,
Gpd1l, and Armc10 were upregulated compared to naive mice,
whileMsra, Hba-a1/2, and Krt34 were downregulated. These pro-
teins are involved in responses to stress and metabolic processes
(Fig. 4). PCA also showed that the levels of protein expression in
lungs from VV-wt and naive mice, both naive to RSV, are highly
similar and explained why only 6 differentially expressed proteins
were observed (Fig. 3C).
There were many similarities between rVV-F- and rVV-G-
primed animals in the alterations of protein expression (Fig. 3). A
total of 65 proteins were differentially expressed in the two groups
of mice compared to naive mice, and these mainly included pro-
teins involved in metabolic processes and responses to stress (Fig.
4). A total of 63 proteins were differentially expressed only in
rVV-F-vaccinated mice and a total of 32 only in rVV-G-vacci-
nated mice. In both groups, the majority of differentially ex-
FIG 3 Proteome analysis of lung samples. (A) Distribution of the number of proteins identified in each group of vaccinated mice upon RSV challenge. (B) PCA
of all lung proteome samples on the basis of normalized spectral counts. The first principal component (PC1) and the second principal component (PC2) are
depicted on the x axis and the y axis. (C) Numbers of identified and validated proteins that were upregulated (black numbers) or downregulated (gray numbers)
upon RSV challenge in response to VV-wt, rVV-F, or rVV-G vaccination compared to the results seen with naive mice.
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pressed proteins, involving similar numbers and biological pro-
cesses, were upregulated (Fig. 3 and 4).
Proteins are known to be involved in multiple pathways and,
hence, are likely to have multiple functions. Pathway analysis (In-
genuity) was performed for further functional classification of dif-
ferentially expressed proteins and to investigate the presumed in-
teractions between these proteins within specific functional
categories. A substantial proportion of the proteins differentially
expressed in both rVV-F- and rVV-G-primed mice compared to
naive mice appeared to play a role in antigen presentation (7.2%),
biosynthesis (6.6%), or metabolism (7.8%), but the majority of
the proteins were involved in immune and defense responses
(16.3%). Within the latter group of differentially expressed pro-
teins, five (Npm1, Snd1, Kars, Krt18, and Eif4a1) have been re-
ported to be involved in host-virus interactions and another eight
(BstI, Bst2, Gbp3, Ifit1, Ifit2, Ifit3, Ddx21, and Gbp1) have been
shown to be active in antiviral immune responses. Within this
group of proteins involved in antiviral immune responses, Gbp3,
Ifit2, and Ddx21 were found to be upregulated compared to the
levels in naive mice in rVV-F-primed mice only, while Bst2, Ifit1,
Ifit3, and Gbp1 were upregulated in both rVV-F- and rVV-G-
primed mice. A first line of defense against virus infections is
formed by the type I interferon (IFN)-induced proteins. Five pro-
teins in the list of differentially expressed proteinswere involved in
this defense response. Ifit1, Ifit2, and Ifit3 are members of the
family of interferon-induced proteins with tetratricopeptide re-
peats (IFITs), and Gbp1 and Gbp3 are members of the family of
IFN-induced guanylate-binding proteins which are all involved in
antiviral responses (23, 24). Ifit1 and Ifit3 were differentially ex-
pressed in rVV-F- and rVV-G-primedmice, while Ifit2 was found
differentially expressed only in rVV-F-primedmice. All three pro-
teins are expressed in the cytoplasm andmitochondria, but Ifit2 is
expressed in microtubules as well and interacts with the cytoskel-
eton, which may explain the difference observed.
TABLE 1 Differentially expressed proteins in rVV-G- versus rVV-F-primed mice upon challenge with RSV
UniProt ID
Gene
product Protein name
Spectral count rVV-G vs rVV-F
rVV-G rVV-F
Fold
change
Adjusted
P value
Q3U1U4 Itgam Integrin alpha-M 3.8 0 Up 0.002
P49290 Epx Eosinophil peroxidase 12.2 1.0 12.1 0
Q61176 Arg1 Arginase 1 18.2 3.1 6.0 0.002
Q9D7Z6 Clca3 Calcium-activated chloride channel regulator 1 6.9 0 Up 0
O35744 Chi3l3 Chitinase-like protein 3 5.7 0 Up 0
Q3TRM8 Hk3 Hexokinase 3 2.8 0 Up 0.041
O35295 Purb Transcriptional activator protein Pur-beta 0 3.5 Down 0.024
FIG 4 Functional classification of differentially expressed proteins. Proteins were grouped by functional categories derived from GO slim and UniProt (http:
//www.uniprot.org/uniprot/). The graph shows the absolute number of differentially expressed proteins that could be assigned to a functional category forVV-wt
(green bars)-, rVV-G (red bars)-, and rVV-F (blue bars)-vaccinated mice upon RSV challenge compared to naive mice.
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DISCUSSION
Vaccines aim to induce antigen-specific memory responses that
mediate safe and effective secondary responses when the host is
exposed to the pathogen. Many live-attenuated and inactivated
virus vaccines have been developed and have collectively reduced
the incidence of disease. However, for RSV and several other vi-
ruses, classical formalin-inactivated vaccine production ap-
proaches failed, as they prime for unbalanced, skewed Th2-type
immune responses upon challenge (7, 25, 26). These hypersensi-
tivity responses are associated with immune pathology and are
marked by peribronchiolarmonocytic infiltration, including neu-
trophils and eosinophils (27). In this study, we explored the well-
established rVV-RSV vaccination-challenge mouse model to
identify protein markers and regulatory mechanisms that are as-
sociated with or that underlie vaccine-induced aberrant host re-
sponses. Comparing lung tissue samples from rVV-F- and rVV-
G-primed animals with control samples from naive mice, we
identified many differentially regulated proteins. These proteins
are involved in metabolic processes and stress, but a significant
proportion were identified as host-immune-response-related
proteins (Table 2). By directly comparing vaccine-induced host
responses, we were able to uncover subtle but highly relevant lung
proteome differences between phenotypically distinct Th1- and
Th2-like host responses. Direct comparison of levels of protein
expression in lung tissue fromRSV-challengedmice that had been
vaccinated with rVV-F and rVV-G identified differential expres-
sion of only 7 proteins: Epx, Chil3, Itgam, Arg1, Clca3, PurB, and
Hk3. These proteins are of particular interest, as their biological
functions can be linked to the vaccination-induced host response
phenotype and immunopathology.
An important feature of RSV-vaccine-primedTh2 skewed host
responses is amarked increase in the influx of eosinophils into the
lungs. As expected, rVV-G-primed mice indeed accumulated sig-
nificant numbers of eosinophils in the lungs (BAL fluid) upon
RSV challenge (Fig. 2). Eosinophil peroxidase (Epx) is expressed
by eosinophils and is localized in the cytoplasmic granules.
Against a background of many other cells present in lung tissue
samples, we could easily detect increased levels of the Epx protein
in the lungs of rVV-G-primed animals (Table 1). Upon RSV chal-
lenge, the Epx protein was present at levels that were much (12-
fold) lower in the lungs of rVV-F-primed animals. The Epx pro-
tein functions as an oxidant and has been shown to be released at
sites of infection to mediate lysis of protozoa or parasitic worms.
Lung histology from the two fatal cases of the FI-RSV trial in the
1960s revealed a pronounced inflammatory lung infiltrate, in-
cluding eosinophils and neutrophils (7, 28). This result has sub-
sequently been reproduced in RSV vaccination-challenge animal
models (29). The association of lung eosinophilia with enhanced
disease in particular has attracted much attention, but it is most
likely a secondary event, since rVV-G-primed eosinophil-defi-
cientmice also display enhanced disease upon challenge with RSV
(30). Nevertheless, vaccine-primed eosinophilia reflects an unbal-
anced host response to be avoided, as influx of these cells is regu-
lated byTh2-type cytokines, including interleukin-4 (IL-4), IL-10,
and IL-13 (31).Unfortunately, we could not detect these cytokines
at the protein level, probably due to the presence of concentra-
tions too low to be detected in a complex mixture of proteins. In
the context of RSV infection, the Epx protein can be used for
vaccine evaluation purposes. Increased EpxmRNA levels have not
been observed in rodent RSV vaccination-challengemodels of en-
hanced disease (11 and unpublished observation).
TheChil3 protein levels are also upregulated in rVV-G-primed
animals relative to those primed with the F protein. Chil3 (chiti-
nase-like-protein 3) is a secretory protein (also known as Ym1)
with in vitro chemotactic activity for T lymphocytes, bonemarrow
polymorphonuclear leukocytes, and eosinophils. In addition, it
has been demonstrated that Chil3 specifically triggers extravasa-
tion of eosinophils. The Chil3 protein shares conserved amino
acid residues with the chitinase family of proteins but also harbors
a conserved CXC chemokine motif near the NH2 terminus (32).
This hybrid type of protein is mainly produced by macrophages
and is localized in the lumen of the rough endoplasmic reticulum
and the nuclear envelope of these cells and of neutrophils (33). In
a murine model of airway hyperresponsiveness (AHR), Chil3
mRNAwas also upregulated in the lungs. Interestingly, upregula-
tion preceded the onset of airway inflammation in this model and
specific inhibition of Chil3 mRNA expression suppressed the in-
duction of eosinophilia (34), supporting the idea of a critical role
for Chil3 in eosinophilic inflammation processes. Upregulation of
Chil3 protein in the rVV-G-primed mice upon RSV challenge
suggests a role forChil3 in the eosinophilia observed in thesemice.
Homing of effector cells in inflamed tissue is facilitated by
many cell adhesion factors. In line with the pronounced influx of
different cell types into the lungs of rVV-F- and rVV-G-primed
animals upon challenge with RSV, we identified Itgam, Itgb2,
Lgals3bp, Lama5, and Tns1 as being differentially expressed rela-
tive to naive animals. However, only the Itgam protein expression
level was found to be significantly increased in lung tissue ob-
tained from rVV-G-vaccinatedmice in direct comparisons to lung
tissue obtained from rVV-G- and rVV-F-primed animals. The
Itgam gene encodes the CD11b integrin (alphaM) polypeptide,
which pairs with the polypeptide integrin beta-2 (Itgb2  CD18
integrin) to form a functional integrin also known as the comple-
ment receptor type 3 (CR3) or macrophage-1 (Mac-I) antigen.
Itgb2 was also upregulated in rVV-G-primed mice, which indi-
cates increased expression of the functional integrin. In contrast to
Itgam, which was detected only in rVV-G-primedmice, Itgb2 was
also found to be upregulated in rVV-F-primed mice compared to
naive mice and with no statistical difference in expression results
compared to rVV-G-primed mice (Table 2). Indeed, Itgam binds
tomultiple ligands and is involved in other biological processes in
addition to cell adhesion (35). Itgam expression was originally
reported to be specific for neutrophils and monocytes/macro-
phages. However, Itgam expression was also induced by IL-5 and
IL-33 in eosinophils (36). In an rVV-G-primed Th2 skewed host
response, Itgam expression can thus mediate the recruitment of
neutrophils as well as of eosinophils to the lungs. The concerted
actions of upregulated Chil3 and Itgam proteins may account for
the high level of influx of eosinophils in the lungs of the rVV-G-
primed animals.
Arginase-I (ArgI) catalyzes the hydrolysis of arginine to orni-
thine and urea and is constitutively expressed in hepatocytes (37)
but has also been recognized as an enzyme involved in the induc-
ible nitric oxide synthase (iNOS) pathway in myeloid cells, which
is predominantly regulated by exogenous stimuli (37, 38). In cells
isolated from human blood, Arg1 expression has been found thus
far only in neutrophils (39). In mice, Arg1 expression has been
reported for alternatively activated macrophages (AAM). AAM
play an important role under Th2-driven pathological conditions
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such as asthma and expression of Arg1 together with Chil3 (40),
suggesting that these macrophages help to orchestrate the Th2
skewed responses in rVV-G-primed enhanced disease. In addi-
tion, the elevated Arg1 levels in lungs from rVV-G-primed mice
compared to those from rVV-F-primed mice may also point to a
role for type 2 innate lymphocytes, since these cells constitutively
express Arg1 (41). Participation of the latter cell type may also be
dependent on the presence of IL-33. This cytokine was not de-
tected in our proteome screen. However, microarray analysis of
lung tissue samples obtained from the same experiment showed
that the level of IL-33 mRNA was increased for rVV-G-primed
samples compared with naive lung samples. In a direct compari-
son between rVV-G- and rVV-F-primed lung tissue samples, the
level of the rVV-G-primed IL-33 lung mRNA signal was higher
but the difference did not reach statistical significance (data not
shown).
TABLE 2 Differentially expressed proteins involved in immune system processes
UniProt ID
Gene
product Protein name
rVV-F vs naive rVV-G vs naive rVV-G vs rVV-F
Fold
change
Adjusted
P value
Fold
change
Adjusted
P value
Fold
change
Adjusted
P value
P04187 Gzmb Granzyme B Up 0.000 Up 0.033
Q02357 Ank1 Ankyrin-1 5.2 0.000 5.9 0.015
P15508 Sptb Spectrin beta chain, erythrocytic 6.2 0.000 30.7 0.011
Q8R2Q8 Bst2 Bone marrow stromal antigen 2 11.7 0.000 11.2 0.004
Q9R233 Tapbp Tapasin Up 0.000 Up 0.002
P08032 Spta1 Spectrin apha chain, erythrocytic 1 7.1 0.000 10.6 0.002
P36371 Tap2 Antigen peptide transporter 2 Up 0.001 Up 0.001
Q64282 Ifit1 Interferon-induced protein with tetratricopeptide repeats 1 Up 0.001 Up 0.001
Q60766 Irgm1 Immunity-related GTPase family M protein 1 Up 0.000 Up 0.000
Q5I2A0 Serpina3g Serine protease inhibitor A3G Up 0.000 Up 0.000
Q64345 Ifit3 Interferon-induced protein with tetratricopeptide repeats 3 Up 0.000 Up 0.000
Q9QZ85 Iigp1 Interferon-inducible GTPase 1 130.7 0.000 98.4 0.000
Q01514 Gbp1 Interferon-induced guanylate-binding protein 1 52.3 0.000 44.2 0.000
O35955 Psmb10 Proteasome subunit beta type-10 35.1 0.000 37.2 0.000
P42225 Stat1 Signal transducer and activator of transcription 1 30.0 0.000 30.0 0.000
P21958 Tap1 Antigen peptide transporter 1 Up 0.000
P01029 C4b Complement C4-B 38.4 0.000
P01863 Ighg Ig gamma-2A chain C region, A allele 8.6 0.000
P29351 Ptpn6 Tyrosine-protein phosphatase nonreceptor type 6 Up 0.001 Up 0.000
P11835 Itgb2 Integrin beta-2 Up 0.001 Up 0.000
P47941 Crkl Crk-like protein Up 0.001
Q61646 Hp Haptoglobin 4.4 0.001
Q9Z0E6 Gbp2 Interferon-induced guanylate-binding protein 2 10.0 0.002 8.3 0.038
Q62418 Dbnl Drebrin-like protein 28.5 0.002
Q06318 Scgb1a1 Uteroglobin 23.0 0.002
Q61107 Gbp4 Guanylate-binding protein 4 Up 0.004
Q8CFB4 Gbp5 Guanylate-binding protein 5 Up 0.006 Up 0.001
P97290 Serping1 Plasma protease C1 inhibitor 9.1 0.006
Q64112 Ifit2 Interferon-induced protein with tetratricopeptide repeats 2 Up 0.007
O89053 Coro1a Coronin-1A 2.8 0.012 3.2 0.012
P02089 Hbb-b2 Hemoglobin subunit beta-2 2.0 0.018
P10711 Tcea1 Transcription elongation factor A protein 1 Up 0.020
P04441 Cd74 H-2 class II histocompatibility antigen gamma chain Up 0.022 Up 0.007
Q9EPB4 Pycard Apoptosis-associated speck-like protein containing a CARD 10.2 0.023 13.5 0.005
P31230 Aimp1 Aminoacyl tRNA synthase complex-interacting
multifunctional protein 1
16.4 0.023
P00493 Hprt Hypoxanthine-guanine phosphoribosyltransferase 3.0 0.024
Q60710 Samhd1 Deoxynucleoside triphosphate triphosphohydrolase SAMHD1 2.2 0.027 2.3 0.030
P18468 H2-Eb1 H-2 class II histocompatibility antigen, I-A beta chain Up 0.028 Up 0.018
Q99JB2 Stoml2 Stomatin-like protein 2, mitochondrial Up 0.028
P01027 C3 Complement C3 2.0 0.042
Q64339 Isg15 Ubiquitin-like protein ISG15 Up 0.045
P09470 Ace Angiotensin-converting enzyme 1.8 0.048 3.9 0.002
Q9EQH2 Erap1 Endoplasmic reticulum aminopeptidase 1 15.7 0.044
Q61233 Lcp1 Plastin-2 2.1 0.040
P16110 Lgals3 Galectin-3 3.5 0.037
P01915 H2-Eb1 H-2 class II histocompatibility antigen, E-D beta chain 17.5 0.032
P49290 Epx Eosinophil peroxidase 34.0 0.007 12.0 0.000
Q3U1U4 Itgam Integrin alpha-M Up 0.001 Up 0.000
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Members of the chloride channel, calcium-activated (CLCA)
family of proteins, including the murine Clca3 (mClca3, alias
gob-5) protein and its human ortholog hCLCA1, have been iden-
tified as relevant molecules in diseases with secretory dysfunc-
tions, including asthma and cystic fibrosis (42). mClca3 is also
upregulated in rVV-G-primed animals relative to rVV-F-primed
animals. Biochemical analysis of the posttranslational processing
and intracellular trafficking of the mClca3 protein showed that it
does not form an anion channel as suggested by the protein name
but is cleaved into two subunits that are fully secreted as a glyco-
sylated protein complex into the extracellular environment (42).
Interestingly, it has been demonstrated that hCLCA1 mRNA lev-
els and protein expression are significantly increased in the airway
epithelium of asthmatic patients (43, 44), and overexpression of
mClca3 inmice resulted in goblet cell metaplasia andmucin over-
production (45). Targeting the mClca3 protein with antibodies
inhibited these processes in asthmatic mice (46). Collectively, the
data suggest that CLCA proteins may also play an important role
in Th2-driven RSV vaccine-induced enhanced lung disease and
that detection of Clca3 protein expression could be used to guide
RSV vaccine design and evaluation.
Both hexokinase III (Hk3) and purine-rich element-binding
protein beta (PurB) have no obvious function in the host response
to infection. Hexokinases catalyze the first step in glucose metab-
olism. Hk3 expression is relatively low in most tissues, with the
highest levels reported in lung, kidney, and liver. Hk3 may play a
role in protecting against cell death, and its overexpression de-
creases the oxidant-induced production of reactive oxygen species
(ROS) (47). In addition to Hk3 exhibiting a protein expression
level that changes due to the influx of specific immune cells, its
metabolic function can be related only indirectly to the observed
host responses. PurB is the only protein that is expressed at lower
levels in rVV-G-primed animals than in rVV-F-primed animals.
PurB is a sequence-specific, single-stranded DNA-binding pro-
tein implicated in the control of both DNA replication and tran-
scription. Defects in this gene are associatedwith the development
of acute myelogenous leukemia, in which some hematopoietic
precursors are arrested in an early stage (48). A nonequal role for
PurB in cell division for the distinct immune cell types present in
the RSV-challenged lungs may contribute to the skewed cell com-
position results observed for the different vaccine priming regi-
mens.
In summary, using proteome analysis, we have identified a set
of host proteins that are differentially expressed between two phe-
notypically distinct secondary immune responses, each ofwhich is
evoked upon challenge with RSV after priming with closely re-
lated, but distinct, RSV vaccine preparations: rVV-F and rVV-G.
Vaccination of mice with rVV-G but not rVV-F prior to RSV
challenge induces typical vaccine-mediated enhanced disease that
is characterized by amarked influx of eosinophils andneutrophils.
The host proteins identified as differentially expressed under the
two sets of vaccination-dependent conditions are involved in pro-
cesses related to the direct influx of eosinophils (Epx) and to che-
motaxis and extravasation (Chil3) as well as in the homing to the
lungs of these cells and neutrophils (Itgam). In addition, the in-
creased protein levels of Arg1 and Chil3 point to a functional and
regulatory role for alternatively activated macrophages and type 2
innate lymphoid cells in Th2 cytokine-driven RSV vaccine-medi-
ated enhanced disease. The identification of those proteins sup-
ports research on regulatory aspects of vaccine-induced skewed
host responses as well as the evaluation of next-generation RSV
vaccines.
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